Affini-T Therapeutics, a trailblazing clinical stage precision immunotherapy company, today announced that it has successfully raised $175,000,000 in a significant funding round. This capital infusion underscores the immense investor confidence in Affini-T’s innovative approach to developing potentially curative therapies that target oncogenic driver mutations—beginning with KRAS—to combat solid tumors. By advancing two distinct T Cell Receptor (TCR) based therapeutic modalities, including adoptive cellular therapies and bispecific T Cell Engagers, Affini-T is setting a new standard in harnessing the body’s T cell immunity with unprecedented precision and potency. The funding will allow the company to accelerate its state-of-the-art engineering, synthetic biology, and gene editing platforms that are revolutionizing TCR T-cell therapies. With its advanced therapies designed for high specificity and durability, Affini-T Therapeutics is well-positioned to overcome the long-standing challenges of effectively targeting and eliminating solid tumors.
This capital raise will be critical in expanding their current pipeline and furthering the development of transformational medicines that can make a lasting impact on patients’ lives. Furthermore, it will bolster the company’s research and development efforts, support clinical trials, and help scale manufacturing capacities to meet future market demands. As a company driven by a world-class leadership team and founded on a foundation of cutting-edge innovation, Affini-T is poised to redefine precision immunotherapy. The funds are also expected to facilitate strategic collaborations and partnerships, which are essential for accelerating the journey of breakthrough therapies from the lab to the clinic, ultimately transforming the landscape of precision oncology and offering renewed hope to patients battling solid tumors.
